ReviewFrontiers in cell and developmental biology2026
Gender differences in adiponectin levels among obese individuals and their association with cardiovascular disease.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is one of the major risk factors for cardiovascular disease Adiponectin, an adipokine with cardioprotective effects, exhibits significant sex differences, with higher plasma levels observed in women. However, the mechanistic basis of this sex difference and its pathophysiological significance in obesity-related cardiovascular disease require further elucidation. This review systematically examines the gender-specific pathways ranging from gonadotropins to adiponectin expression and signalling, as well as how dysregulation of these pathways in the context of obesity leads to cardiac damage. We propose that dysfunction of epicardial adipose tissue acts as a key hub, with local inflammation and alterations in adipokine signalling exacerbating coronary atherosclerosis, myocardial fibrosis and arrhythmias. Furthermore, we have examined the clinical conundrum known as the adiponectin paradox in advanced cardiometabolic diseases. In summary, a deeper understanding of the gender dimorphism of adiponectin is crucial for recognising gender-specific susceptibilities and may provide a strategic basis for future approaches to addressing obesity-mediated cardiovascular complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.